Published in PLoS One on May 28, 2013
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene (2014) 0.86
The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget (2015) 0.85
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine (2016) 0.81
Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Med Genomics (2014) 0.80
Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation. Mol Hum Reprod (2014) 0.77
Marked increase in rat red blood cell membrane protein glycosylation by one-month treatment with a cafeteria diet. PeerJ (2015) 0.76
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. EBioMedicine (2017) 0.75
The steroid and thyroid hormone receptor superfamily. Science (1988) 25.68
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Tyrosine kinases as targets for cancer therapy. N Engl J Med (2005) 6.24
Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell (2007) 4.85
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med (2006) 3.70
Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev (1995) 3.58
Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene (2010) 3.04
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci (2000) 2.52
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell (2011) 2.35
Landmarks in hormonal therapy for prostate cancer. BJU Int (2012) 2.06
O-GlcNAc signaling: a metabolic link between diabetes and cancer? Trends Biochem Sci (2010) 2.05
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology (2003) 1.91
SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal (2010) 1.63
Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem (2012) 1.63
Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol (2011) 1.59
Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem (2006) 1.59
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 1.58
Informed conditioning on clinical covariates increases power in case-control association studies. PLoS Genet (2012) 1.57
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene (2002) 1.55
Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol (2012) 1.53
Adaptive regulation at the cell surface by N-glycosylation. Traffic (2009) 1.50
The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol (2012) 1.29
Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res (2003) 1.27
Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J (2011) 1.16
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate (1995) 1.11
In control at the ER: PTP1B and the down-regulation of RTKs by dephosphorylation and endocytosis. Trends Cell Biol (2010) 1.06
Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res (2009) 1.03
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res (2012) 1.01
Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One (2012) 1.00
Integration of engrafted Schwann cells into injured peripheral nerve: axonal association and nodal formation on regenerated axons. Neurosci Lett (2005) 0.99
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res (2011) 0.99
Insulin-like growth factor 1 stimulation of androgen receptor activity requires β(1A) integrins. J Cell Physiol (2012) 0.93
Proteome analysis of tunicamycin-induced ER stress. Electrophoresis (2012) 0.93
Negative regulation of receptor tyrosine kinase signals. FEBS Lett (2001) 0.93
Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int (2010) 0.87
A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. J Biol Chem (2012) 0.86
The hexosamine biosynthesis pathway is essential for pancreatic beta cell development. J Biol Chem (2009) 0.84
Prostate-specific antigen in screening of prostate cancer. J Clin Lab Anal (1994) 0.83
c-Met function requires N-linked glycosylation modification of pro-Met. J Cell Biochem (2013) 0.81
Chromatin binding by the androgen receptor in prostate cancer. Mol Cell Endocrinol (2011) 0.80
BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. Science (2003) 12.60
Curvature of clathrin-coated pits driven by epsin. Nature (2002) 8.03
Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet (2011) 3.73
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Role of the AP2 beta-appendage hub in recruiting partners for clathrin-coated vesicle assembly. PLoS Biol (2006) 2.71
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59
COP and clathrin-coated vesicle budding: different pathways, common approaches. Curr Opin Cell Biol (2004) 2.49
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep (2007) 2.17
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J (2010) 1.93
Evolving nature of the AP2 alpha-appendage hub during clathrin-coated vesicle endocytosis. EMBO J (2004) 1.87
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest (2012) 1.85
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. Dev Cell (2004) 1.62
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
ChIPping away at gene regulation. EMBO Rep (2008) 1.54
Structural basis for the nuclear import of the human androgen receptor. J Cell Sci (2008) 1.53
Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One (2015) 1.48
LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin Cancer Res (2009) 1.41
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res (2013) 1.31
The developing role of receptors and adaptors. Nat Rev Cancer (2006) 1.21
A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics (2007) 1.17
Alterations in beta-catenin expression and localization in prostate cancer. Prostate (2008) 1.16
The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol (2012) 1.12
Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate (2008) 1.08
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol (2012) 1.02
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med (2014) 0.98
Pro-neural transcription factors as cancer markers. BMC Med Genomics (2008) 0.97
Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol (2010) 0.95
Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis (2009) 0.94
Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients. Int J Cancer (2013) 0.90
A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate (2007) 0.89
Solitary and repetitive binding motifs for the AP2 complex alpha-appendage in amphiphysin and other accessory proteins. J Biol Chem (2007) 0.88
Nuclear trafficking and functions of endocytic proteins implicated in oncogenesis. Traffic (2009) 0.83
Global identification of androgen response elements. Methods Mol Biol (2011) 0.83
Clathrin is spindle-associated but not essential for mitosis. PLoS One (2008) 0.82
Chromatin immunoprecipitation (ChIP) methodology and readouts. Methods Mol Biol (2009) 0.81
Chromatin binding by the androgen receptor in prostate cancer. Mol Cell Endocrinol (2011) 0.80
Putting chromatin immunoprecipitation into context. J Cell Biochem (2009) 0.79
Novel role of androgens in mitochondrial fission and apoptosis. Mol Cancer Res (2011) 0.78
AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. Cell Cycle (2008) 0.77
Terminal and progenitor lineage-survival oncogenes as cancer markers. Trends Mol Med (2008) 0.77
Mapping protein-DNA interactions using ChIP-sequencing. Methods Mol Biol (2012) 0.76
Correction: Abundant Genetic Overlap between Blood Lipids and Immune-Mediated Diseases Indicates Shared Molecular Genetic Mechanisms. PLoS One (2015) 0.75
Bridging the gaps: from risk loci via non-coding RNAs to gene networks and prostate cancer phenotypes. Cell Cycle (2011) 0.75
Studying N-linked glycosylation of receptor tyrosine kinases. Methods Mol Biol (2015) 0.75